Long term use of drugs affecting the renin-angiotensin system and the risk of cancer: A population-based case-control study

British Journal of Clinical Pharmacology

Volumn 74, Issue 1, 2012, Pages 180-188

  Hallas, Jesper ^a   Christensen, Rene ^a   Andersen, Morten ^a,b   Friis, Søren ^c   Bjerrum, Lars ^d  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b KAROLINSKA INSTITUTE   (Sweden)

^c INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Angiotensin converting enzyme inhibitors; Angiotensin receptor blockers; Antihypertensives; Cancer; Case controls study

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPROSARTAN; FOSINOPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; MOEXIPRIL; OLMESARTAN; PERINDOPRIL; QUINAPRIL; RAMIPRIL; TELMISARTAN; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; VALSARTAN;

ARTICLE; BREAST CANCER; CANCER RISK; COLON CANCER; DENMARK; HEMATOLOGIC MALIGNANCY; HUMAN; LUNG CANCER; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DENMARK; FEMALE; HUMANS; INFANT; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASMS; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; YOUNG ADULT;

EID: 84862152929     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2012.04170.x     Document Type: Article

References (41)

1. Ma TK, Kam KK, Yan BP, Lam YY. Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol 2010; 160: 1273-92.
2. Deshayes F, Nahmias C. Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 2005; 16: 293-9.
3. Moskowitz DW, Johnson FE. The central role of angiotensin I-converting enzyme in vertebrate pathophysiology. Curr Top Med Chem 2004; 4: 1433-54.
4. Escobar E, Rodriguez-Reyna TS, Arrieta O, Sotelo J. Angiotensin II, cell proliferation and angiogenesis regulator: biologic and therapeutic implications in cancer. Curr Vasc Pharmacol 2004; 2: 385-99.
5. Walther T, Menrad A, Orzechowski HD, Siemeister G, Paul M, Schirner M. Differential regulation of in vivo angiogenesis by angiotensin II receptors. FASEB J 2003; 17: 2061-7.
6. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S, CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759-66.
7. Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC. Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol 2010; 11: 627-36.
8. Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, Meredith PA, Murray LS, Reid JL, Robertson JW. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 1998; 352: 179-84.
9. Jick H, Jick S, Derby LE, Vasilakis C, Myers MW, Meier CR. Calcium-channel blockers and risk of cancer. Lancet 1997; 349: 525-8.
10. Lindholm LH, Anderson H, Ekbom T, Hansson L, Lanke J, Dahlöf B, de Faire U, Forsén K, Hedner T, Linjer E, Scherstén B, Wester P, Möller T. Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trial. Lancet 2001; 358: 539-44.
11. Friis S, Sørensen HT, Mellemkjaer L, McLaughlin JK, Nielsen GL, Blot WJ, Olsen JH. Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. Cancer 2001; 92: 2462-70.
12. Li CI, Malone KE, Weiss NS, Boudreau DM, Cushing-Haugen KL, Daling JR. Relation between use of antihypertensive medications and risk of breast carcinoma among women aged 65-79 years. Cancer 2003; 98: 1504-13.
13. Gonzalez-Perez A, Ronquist G, Garcia Rodriguez LA. Breast cancer incidence and use of antihypertensive medication in women. Pharmacoepidemiol Drug Saf 2004; 13: 581-5.
14. Meier CR, Derby LE, Jick SS, Jick H. Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer. Arch Intern Med 2000; 160: 349-53.
15. Perron L, Bairati I, Harel F, Meyer F. Antihypertensive drug use and the risk of prostate cancer (Canada). Cancer Causes Control 2004; 15: 535-41.
16. Stahl M, Bulpitt CJ, Palmer AJ, Beevers DG, Coles EC, Webster J. Calcium channel blockers, ACE inhibitors, and the risk of cancer in hypertensive patients: a report from the Department of Health Hypertension Care Computing Project (DHCCP). J Hum Hypertens 2000; 14: 299-304.
17. Fryzek JP, Poulsen AH, Lipworth L, Pedersen L, Nørgaard M, McLaughlin JK, Friis S. A cohort study of antihypertensive medication use and breast cancer among Danish women. Breast Cancer Res Treat 2006; 97: 231-6.
18. Ronquist G, Rodríguez LA, Ruigómez A, Johansson S, Wallander MA, Frithz G, Svärdsudd K. Association between captopril, other antihypertensive drugs and risk of prostate cancer. Prostate 2004; 58: 50-6.
19. Sleight P. The HOPE Study (Heart Outcomes Prevention Evaluation). J Renin Angiotensin Aldosterone Syst 2000; 1: 18-20.
20. Grossman E, Messerli FH, Goldbourt U. Antihypertensive therapy and the risk of malignancies. Eur Heart J 2001; 22: 1343-52.
21. Fryzek JP, Poulsen AH, Johnsen SP, McLaughlin JK, Sørensen HT, Friis S. A cohort study of antihypertensive treatments and risk of renal cell cancer. Br J Cancer 2005; 92: 1302-6.
22. Pasternak B, Svanström H, Callréus T, Melbye M, Hviid A. Use of angiotensin receptor blockers and the risk of cancer. Circulation 2011; 123: 1729-36.
23. Hallas J, Friis S, Bjerrum L, Støvring H, Narverud SF, Heyerdahl T, Grønbæk K, Andersen M. Cancer risk in long-term users of valproate: A population based case-control study. Cancer Epidemiol Biomarkers Prev 2009; 18: 1714-9.
24. Storm HH, Michelsen EV, Clemmensen IH, Pihl J. The Danish Cancer Registry - history, content, quality and use. Dan Med Bull 1997; 44: 535-9.
25. Andersen TF, Madsen M, Jorgensen J, Mellemkjaer L, Olsen JH. The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull 1999; 46: 263-8.
26. Gaist D, Sørensen HT, Hallas J. The Danish prescription registries. Dan Med Bull 1997; 44: 445-8.
27. WHO Collaborating Centre for Drug Statistics Methodology, Norwegian Institute of Public Health 2011. ATC/DDD index. Available at (last accessed 12 February 2012).
28. Rothman K. Epidemiology, an Introduction. Oxford: Oxford Press, 2002; 78.
29. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-83.
30. Stata Press. Stata for Windows. College Station, TX: Stata Statistical Software, 1999.
31. The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
32. Tetsche MS, Nørgaard M, Skriver MV, Andersen ES, Lash TL, Sørensen HT. Accuracy of ovarian cancer ICD-10 diagnosis in a Danish population-based hospital discharge registry. Eur J Gynaecol Oncol 2005; 26: 266-70.
33. Nørgaard M, Skriver MV, Gregersen H, Pedersen G, Schønheyder HC, Sørensen HT. The data quality of haematological malignancy ICD-10 diagnoses in a population-based hospital discharge registry. Eur J Cancer Prev 2005; 14: 201-6.
34. Danish Medicines Agency 2011. Statistics, prices and reimbursement. Available at (last accessed 12 February 2012).
35. Merlo J, Asplund K, Lynch J, Råstam L, Dobson A, for the World Health Organization MONICA Project. Population effects on individual systolic blood pressure: a multilevel analysis of the World Health Organization MONICA project. Am J Epidemiol 2004; 159: 1168-79.
36. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, Sever PS, Thom SM, BHS guidelines working party, for the British Hypertension Society. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004; 328: 634-40.
37. Taubes G. Epidemiology faces its limits. Science 1995; 269: 164-9.
38. Austin H, Hill HA, Flanders WD, Greenberg RS. Limitations in the application of case-control methodology. Epidemiol Rev 1994; 16: 65-76.
39. Bangalore S, Kumar S, Kjeldsen SE, Makani H, Grossman E, Wetterslev J, Gupta AK, Sever PS, Gluud C, Messerli FH. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324, 168 participants from randomised trials. Lancet Oncol 2011; 12: 65-82.
40. Mørch LS, Løkkegaard E, Andreasen AH, Krüger-Kjaer S, Lidegaard O. Hormone therapy and ovarian cancer. JAMA 2009; 302: 298-305.
41. Beral V, Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 419-27.